Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q15708300> ?p ?o }
Showing triples 1 to 51 of
51
with 100 triples per page.
- Q15708300 subject Q8341873.
- Q15708300 subject Q8375173.
- Q15708300 subject Q8543773.
- Q15708300 subject Q8955377.
- Q15708300 abstract "ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982 and has been reported to be a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 1.2 nM and 3.5 nM respectively. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135. ADB-FUBINACA appears to be the product of rational drug design, since it differs from AB-FUBINACA only by the replacement of the isopropyl group with a tert-butyl group.An analogue of ADB-FUBINACA, ADSB-FUB-187, containing a more functionalized carboxamide substituent was recently reported.".
- Q15708300 casNumber "1445583-51-6".
- Q15708300 iupacName "N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide".
- Q15708300 pubchem "70969086".
- Q15708300 thumbnail ADB-FUBINACA_structure.png?width=300.
- Q15708300 wikiPageWikiLink Q1200715.
- Q15708300 wikiPageWikiLink Q15708301.
- Q15708300 wikiPageWikiLink Q17907844.
- Q15708300 wikiPageWikiLink Q18209025.
- Q15708300 wikiPageWikiLink Q19595738.
- Q15708300 wikiPageWikiLink Q206921.
- Q15708300 wikiPageWikiLink Q20706931.
- Q15708300 wikiPageWikiLink Q20706945.
- Q15708300 wikiPageWikiLink Q20707112.
- Q15708300 wikiPageWikiLink Q20707134.
- Q15708300 wikiPageWikiLink Q20707142.
- Q15708300 wikiPageWikiLink Q20707198.
- Q15708300 wikiPageWikiLink Q20707300.
- Q15708300 wikiPageWikiLink Q20707333.
- Q15708300 wikiPageWikiLink Q21098932.
- Q15708300 wikiPageWikiLink Q21163314.
- Q15708300 wikiPageWikiLink Q253623.
- Q15708300 wikiPageWikiLink Q261327.
- Q15708300 wikiPageWikiLink Q3803305.
- Q15708300 wikiPageWikiLink Q389934.
- Q15708300 wikiPageWikiLink Q4391382.
- Q15708300 wikiPageWikiLink Q4650002.
- Q15708300 wikiPageWikiLink Q4650003.
- Q15708300 wikiPageWikiLink Q4653308.
- Q15708300 wikiPageWikiLink Q656556.
- Q15708300 wikiPageWikiLink Q7119044.
- Q15708300 wikiPageWikiLink Q7394830.
- Q15708300 wikiPageWikiLink Q8341873.
- Q15708300 wikiPageWikiLink Q8375173.
- Q15708300 wikiPageWikiLink Q8543773.
- Q15708300 wikiPageWikiLink Q8955377.
- Q15708300 casNumber "1445583".
- Q15708300 iupacName "N--1--1H-indazole-3-carboxamide".
- Q15708300 pubchem "70969086".
- Q15708300 type ChemicalSubstance.
- Q15708300 type Drug.
- Q15708300 type ChemicalObject.
- Q15708300 type Thing.
- Q15708300 type Q8386.
- Q15708300 comment "ADB-FUBINACA is a designer drug identified in synthetic cannabis blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982 and has been reported to be a potent agonist of the CB1 receptor and CB2 receptor with an EC50 value of 1.2 nM and 3.5 nM respectively. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like SDB-001 and STS-135.".
- Q15708300 label "ADB-FUBINACA".
- Q15708300 depiction ADB-FUBINACA_structure.png.